Novel prostate cancer marker may lead to earlier diagnosis and fewer repeat bioposies
Findings published in this months issue of the Journal of Urology indicate that prostate cancer could be detected as many as five years earlier than it is currently being diagnosed by testing for a protein in tissue that indicates the presence of early disease. The researchers suggest that testing for the protein, EPCA, could serve as an adjunct to the current diagnostic approach to patients with elevated levels of prostate-specific antigen, or PSA, who undergo repeat needle biopsies. PSA, a substance in the blood released by the prostate gland, is commonly used to check for signs of prostate cancer and other prostate problems.
"One of the problems with testing for levels of PSA as an indicator of prostate cancer is that PSA levels often fluctuate up and down, making it difficult to know for certain whether a man has prostate cancer without performing multiple biopsies over time," said Robert Getzenberg, Ph.D., senior author and professor of urology, pathology and pharmacology at the University of Pittsburgh School of Medicine. "By testing for EPCA in men with high levels of PSA, we may be able to detect the presence of prostate cancer earlier, before it is discoverable by biopsy, saving patients the fear and stress of repeat procedures and enabling us to treat the disease sooner."
Dr. Getzenberg explained that EPCA is a marker protein that indicates the earliest changes that occur in cells during the development of cancer.
In the study, Dr. Getzenberg, also co-director of the Prostate and Urologic Cancer Program at the University of Pittsburgh Cancer Institute, and colleagues developed antibodies against EPCA to detect its presence in tissue. They compared 27 non-diseased control tissue samples to 29 tissue samples from patients with prostate cancer who had initial negative biopsies. They found that the samples from the negative biopsies of those patients who were eventually diagnosed with prostate cancer expressed EPCA and that EPCA was not expressed in tissue samples from individuals without disease. They also found that EPCA was not only expressed in the tumor, but throughout the prostate in men with prostate cancer indicating its usefulness as a prognostic marker for prostate cancer.
A multi-center study is currently underway to further assess the usefulness of EPCA and its possible use as a biomarker for prostate cancer.
Prostate cancer exceeds lung cancer as the most commonly diagnosed cancer among men in the United States with 220,900 new cases and 28,900 deaths in 2003. More than 70 percent of all prostate cancer cases are diagnosed in men over age 65.
The study was supported by a grant from Tessera Inc., Seattle, Wash. Co-authors include Rajiv Dhir, Ph.D., Barbara N. Vietmeier, Julie Arlotti, Ph.D., Marie Acquafondata, Ph.D., and Douglas Landsittel, Ph.D., of the University of Pittsburgh School of Medicine and Robert Materson, Ph.D., of Tessera Inc.
Clare Collins | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...